<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307812</url>
  </required_header>
  <id_info>
    <org_study_id>15263</org_study_id>
    <secondary_id>I4T-FR-JVCS</secondary_id>
    <nct_id>NCT02307812</nct_id>
  </id_info>
  <brief_title>Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France</brief_title>
  <official_title>Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      The treating physician/investigator contacts Lilly when, based on their medical opinion, a&#xD;
      patient meets the criteria for inclusion in the ATU.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Administered intravenously (IV)</description>
    <other_name>IMC-1121B</other_name>
    <other_name>LY3009806</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered IV</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant has histologically or cytologically confirmed gastric adenocarcinoma,&#xD;
             including gastroesophageal junction (GEJ) adenocarcinoma (Participants with&#xD;
             adenocarcinoma of the distal esophagus are eligible if the primary tumor involves the&#xD;
             GEJ.) after prior chemotherapy.&#xD;
&#xD;
          -  Acceptable prior chemotherapy regimens for this protocol are combination chemotherapy&#xD;
             regimens that include platinum or fluoropyrimidine components (acceptable prior&#xD;
             platinum agents are cisplatin, carboplatin, or oxaliplatin; acceptable prior&#xD;
             fluoropyrimidine agents are 5-fluorouracil (5-FU) and capecitabine). Prior trastuzumab&#xD;
             use in human epidermal growth factor receptor 2 positive (HER2+) participants is&#xD;
             accepted too.&#xD;
&#xD;
          -  The participant is eligible for treatment by chemotherapy and has an Eastern&#xD;
             Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has a known allergy to any of the treatment components.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>November 25, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

